Meeting
2023 ASCO Annual Meeting
Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
Authors
Amir Goldkorn
Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
Amir Goldkorn , Catherine Tangen , Melissa Plets , Daniel Bsteh , Tong Xu , Jacek K. Pinski , Sue Ingles , Timothy Junius Triche , Gary R. MacVicar , Daniel A. Vaena , Anthony W. Crispino , David James McConkey , Primo N Lara Jr., Maha H. A. Hussain , David I. Quinn , Tanya B. Dorff , Ian Thompson Jr., Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5080)
DOI
10.1200/JCO.2023.41.16_suppl.5080
Abstract #
5080
Poster Bd #
174
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
First Author: Mamta Parikh
Poster
2016 ASCO Annual Meeting
Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).
First Author: Amir Goldkorn
Poster
2023 ASCO Annual Meeting
Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.
First Author: Nicolas Sayegh
Poster
2024 ASCO Genitourinary Cancers Symposium
Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial.
First Author: Georges Gebrael